Altimmune, Inc.
General ticker "ALT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $414.0M (TTM average)
Altimmune, Inc. does not follow the US Stock Market performance with the rate: -9.1%.
Estimated limits based on current volatility of 4.3%: low 4.85$, high 5.29$
Factors to consider:
- Total employees count: 59 as of 2024
- Top business risk factors: Regulatory and compliance, Clinical trial delays, Manufacturing risks, Labor/talent shortage/retention, Economic downturns and volatility
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.79$, 9.83$]
- 2025-12-31 to 2026-12-31 estimated range: [2.95$, 7.84$]
Financial Metrics affecting the ALT estimates:
- Negative: with PPE of -5.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -14.49 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 88.66 > 63.39
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ALT quotes
Long-term ALT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.43MM | $0.02MM |
| Operating Expenses | $87.74MM | $96.36MM | $103.19MM |
| Operating Income | $-87.74MM | $-95.93MM | $-103.17MM |
| Non-Operating Income | $2.83MM | $7.48MM | $8.11MM |
| Interest Expense | $0.01MM | $0.04MM | $0.01MM |
| R&D Expense | $70.54MM | $65.80MM | $82.23MM |
| Income(Loss) | $-84.91MM | $-88.45MM | $-95.06MM |
| Taxes | $-0.20MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-84.71MM | $-88.45MM | $-95.06MM |
| Stockholders Equity | $185.29MM | $194.10MM | $123.51MM |
| Assets | $206.93MM | $210.64MM | $139.31MM |
| Operating Cash Flow | $-62.59MM | $-75.81MM | $-79.85MM |
| Capital expenditure | $0.13MM | $0.05MM | $0.00MM |
| Investing Cash Flow | $-73.40MM | $13.73MM | $-28.39MM |
| Financing Cash Flow | $56.78MM | $86.11MM | $10.04MM |
| Earnings Per Share** | $-1.81 | $-1.66 | $-1.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.